[Korea Biomedical Review] GC said that it has partnered with Atomwise, a U.S. artificial intelligence-based drug development firm, to discover a new treatment candidate for hemophilia.
Tag Archives: Partnership
[BioSpace] Atomwise, the leader in using artificial intelligence (AI) for small molecule drug discovery, announced today a partnership with GC Pharma (KRX: 006280), a South Korean biopharmaceutical company formerly known as Green Cross Corporation, to discover and develop novel hemophilia therapies. GC Pharma is a pioneer in vaccines and protein therapeutics and has long been dedicated to […]
The partnership will develop new drug programs that advance GC Pharma’s global leadership in hemophilia and additional disease areas SAN FRANCISCO & YONGIN, South Korea–(BUSINESS WIRE)–Atomwise, the leader in using artificial intelligence (AI) for small molecule drug discovery, announced today a partnership with GC Pharma (KRX: 006280), a South Korean biopharmaceutical company formerly known as Green Cross […]
Atomwise and Hansoh successfully identified potent hit compounds each having unique composition of matter for their first AI discovery program against drug-resistant oncology targets SHANGHAI & SAN FRANCISCO–(BUSINESS WIRE)– Hansoh Pharma (3692:HK), a leading biopharmaceutical company in China, and Atomwise, the leader in artificial intelligence (AI) for drug discovery, today announced the expansion of their strategic partnership for […]
The collaboration will discover and develop up to 13 small molecule programs, initially targeting Pellino proteins to treat multiple indications, including inflammation SAN FRANCISCO & SEONGNAM, South Korea–(BUSINESS WIRE)–Atomwise, the leader in using artificial intelligence (AI) for small molecule discovery, and Bridge Biotherapeutics (KOSDAQ: 288330), a clinical stage biotech company, announced today a research collaboration to launch […]
The collaboration will discover and develop up to 13 small molecule programs, initially targeting Pellino proteins to treat multiple indications SAN FRANCISCO–(BUSINESS WIRE)–Atomwise, the leader in using artificial intelligence (AI) for small molecule discovery, and Bridge Biotherapeutics, a clinical stage biotech company, announced today a research collaboration to launch up to 13 small molecule programs […]